Cover Image
市場調查報告書

生物晶片的全球市場:各國(美國、加拿大、印度、中國、日本、英國)、企業簡介、佔有率、趨勢、分析、機會、市場區隔及2015∼2021年的預測

Global Biochips Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 346106
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
生物晶片的全球市場:各國(美國、加拿大、印度、中國、日本、英國)、企業簡介、佔有率、趨勢、分析、機會、市場區隔及2015∼2021年的預測 Global Biochips Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年03月22日 內容資訊: 英文 140 Pages
簡介

全球生物晶片市場預計從2015年到2021年以年複合成長率18%擴大。現在生物晶片市場由於新用途的發現和現有技術的開發而急速擴大,不過,帶動這個成長的是個人化醫療市場擴大和政府支出的增加、醫療預算的投資、文明病的罹患率上升等。

本報告提供全球生物晶片市場相關調查、市場趨勢以及到2021年的收益預測與成長率、產業分析、競爭趨勢、各地區趨勢,及進入的主要企業簡介彙整。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 指標分析
  • 市場趨勢
  • 競爭情報
  • 價值鏈分析
  • 主要的購買標準
  • 策略性建議
  • 策略性結論

第3章 市場決策因素

  • 推動市場的要素
    • 個人化醫療的擴大
    • 政府及民間融資的擴大
    • 癌症診斷和治療的增加
    • 技術創新
    • 文明病和其他新疾病的增加
    • 技術進步
    • 醫療費的擴大
    • 大企業的研究開發
  • 阻礙市場的要素
    • 生物晶片的準確度不足誤導的分析
    • 藥物、醫療設備、蛋白質生物標記的翻譯率低
  • 市場課題
    • 生物晶片中診斷需要的經費高
    • 對於生物晶片市場引進的意識
  • 市場機會
    • 不久的將來,經濟試劑之創新的檢測技術將登場
    • 亞太地區的未開發地區有眼科藥品及設備市場的大幅可能性
    • 實驗室晶片技術的引進擴大

第4章 部門分析

第5章 市場區隔

  • 各用途
  • 各類型
  • 各終端用戶

第6章 競爭情報

  • 市場佔有率
  • 策略

第7章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 企業分析

  • Agilent technologies
  • Affymetrix inc
  • Gene system inc
  • Agendia BV inc
  • Customarray inc
  • Digital genomics inc
  • Bio chain institute Inc
  • Biomerieux SA
  • Bio-rad laboratories inc
  • Cepheid Inc
  • Caliper life sciences inc
  • Cybrdi inc
  • EMD Millipore
  • Elim Biopharmaceuticals
  • Falcon Genomics.
  • Genalyte
  • Oxford gene technology
  • Wafergen biosystems inc
  • Predictive biosciences
  • Fluidigm corp
  • Gamida for life group
  • Illumina Inc
  • Life technologies corp
  • Origene technologies Inc
  • Perkinelmer inc
  • Roche nimblegen inc
  • Sequenom
  • Sigma aldrich corp
  • Imgenex
  • ISU ABXIS co. ltd
  • Quantalife inc

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HME-1371015

A Biochip is a collection of miniaturized test sites (microarrays) arranged on a solid substrate that can perform hundreds or thousands of simultaneous biochemical reactions in order to achieve higher throughput and speed. Biochips help researchers to quickly see large number of biological analytics and are used in a range of research applications within the biotechnology sector, including pharmaceuticals, proteomics and genomics. Biochips are also used in analysis of organic molecules associated with living organisms and help in identifying gene sequences, airborne toxins, environmental pollutants and other biochemical constituents. Although, biochips have been developed and commercialized in mid eighties but the market has transformed in the starting of last decade

Presently, the biochips market is undergoing rapid expansion with the discovery of new applications and the development of existing technologies. The key driving forces for the market of biochips are: growth in personalized medicine market, increase in government spending/ private investment in healthcare budgets and R&D respectively, rising case of lifestyle related diseases and so on. Various factors such as less accuracy of biochips that may lead to wrong analysis, low rate of translation of discoveries in drugs, medical devices and protein biomarkers, low acceptance due to high cost and availability of alternative technologies are restraining the growth of biochips market.

The key players in global biochips market are Agilent technologies Affymetric Inc, Gene system Inc, Agendia BV Inc, Customarray inc, Digital genomics inc, Bio chain institute Inc, Biomerieux SA , Bio-rad laboratories inc, Cepheid Inc, Caliper life sciences Inc, Cybrdi Inc, EMD Millipore, Elim Biopharmaceuticals, Falcon Genomics, Genalyte and so on.

Companies profiled in this report

  • 1. Agilent technologies
  • 2. Affymetrix inc
  • 3. Gene system inc
  • 4. Agendia BV inc
  • 5. Customarray inc
  • 6. Digital genomics inc
  • 7. Bio chain institute Inc
  • 8. Biomerieux SA
  • 9. Bio-rad laboratories inc
  • 10. Cepheid Inc
  • 11. Caliper life sciences inc
  • 12. Cybrdi inc
  • 13. EMD Millipore
  • 14. Elim Biopharmaceuticals
  • 15. Falcon Genomics
  • 16. Genalyte
  • 17. Oxford gene technology
  • 18. Wafergen biosystems inc
  • 19. Predictive biosciences
  • 20. Fluidigm corp
  • 21. Gamida for life group
  • 22. Illumina Inc
  • 23. Life technologies corp
  • 24. Origene technologies Inc
  • 25. Perkinelmer inc
  • 26. Roche nimblegen inc
  • 27. Sequenom
  • 28. Sigma aldrich corp
  • 29. Imgenex
  • 30. ISU ABXIS co ltd
  • 31. Quantalife inc

This Occams Research Report covers

  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR upto 2022
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data
  • 6. In-depth profiling of companies

Table of Contents

1. Introduction

  • 1.1. Executive summary
  • 1.2. Estimation methodology

2. Market overview

  • 2.1. Market definition and scope
  • 2.2. Key findings
  • 2.3. Parametric analysis
    • 2.3.1. Prevalence of life style oriented diseases
    • 2.3.2. Incidence and prevalence rate of cancer
    • 2.3.3. Adoption of biochips in major hospitals and clinics across geographies
    • 2.3.4. Adoption of diagnostics through biochips in research centers
    • 2.3.5. Growing healthcare expenditure across geographies
  • 2.4. Key market insights
    • 2.4.1. Top 3 emerging countries
    • 2.4.2. Top 3 revenue generating segments
    • 2.4.3. Top growing markets and emerging trends
    • 2.4.4. R&D scenario in biochips market
      • 2.4.4.1. Human genome project
      • 2.4.4.2. Silicon technology for electronic biochip
  • 2.5. Competitive intelligence
    • 2.5.1. Market share analysis
    • 2.5.2. Top winning strategies
    • 2.5.3. Case studies: top competitive moves
  • 2.6. Value chain analysis
  • 2.7. Key buying criteria
  • 2.8. Strategic recommendation
  • 2.9. Strategic conclusions

3. Market determinants

  • 3.1. Market drivers
    • 3.1.1. Global growth in personalized medicines
    • 3.1.2. Global increase in government and private funding
    • 3.1.3. Increase in cancer diagnostics and treatment
    • 3.1.4. Innovation giving rise to biochips market
    • 3.1.5. Global increase in life style oriented disease and other new diseases
    • 3.1.6. Technological advancement
    • 3.1.7. Global increase in healthcare expenditure
    • 3.1.8. Increase in r&d from major players
  • 3.2. Market restraints
    • 3.2.1. Less accuracy of biochips may lead to wrong analysis
    • 3.2.2. Low rate of translation of discoveries in drugs, medical devices and protein biomarkers
  • 3.3. Market challenges
    • 3.3.1. High expertise required for the diagnosis through biochips
    • 3.3.2. Creating awareness for increasing adoption of biochip market
  • 3.4. Market opportunities
    • 3.4.1. Innovative detection technology with economic reagents to come in near future
    • 3.4.2. Untapped APAC region has huge scope for ophthalmology drug and device market
    • 3.4.3. Increase in adoption of lab-on-chip technology

4. Sector Analysis

  • 4.1. Parent market
  • 4.2. Sub-segment market
  • 4.3. Alternative market

5. Market Segmentation

  • 5.1. Global biochips market by application
    • 5.1.1. Global DNA micro array market by application, 2014-2021,($ millions)
      • 5.1.1.1. Global gene expression market, 2014-2021,($ millions)
      • 5.1.1.2. Global SNP genotyping market, 2014-2021,($ millions)
      • 5.1.1.3. Global Cancer diagnosis and treatment market, 2014-2021,($ millions)
      • 5.1.1.4. Global Genomics, 2014-2021,($ millions)
      • 5.1.1.5. Global drug discovery market , 2014-2021,($ millions)
      • 5.1.1.6. Global other DNA micro array market, 2014-2021,($ millions)
    • 5.1.2. Global Lab on a chip market by application , 2014-2021,($ millions)
      • 5.1.2.1. Global Genomics market s, 2014-2021,($ millions)
      • 5.1.2.2. Global proteomics market, 2014-2021,($ millions)
      • 5.1.2.3. Global drug discovery, 2014-2021 market,($ millions)
      • 5.1.2.4. Global diagnostics market, 2014-2021,($ millions)
      • 5.1.2.5. Global other lab on chip market, 2014-2021,($ millions)
    • 5.1.3. Global protein microarray market by application , 2014-2021,($ millions)
      • 5.1.3.1. Global expression profiling market , 2014-2021,($ millions)
      • 5.1.3.2. Global proteomics market, 2014-2021,($ millions)
      • 5.1.3.3. Global high throughput screening market, 2014-2021,($ millions)
      • 5.1.3.4. Global diagnostic market, 2014-2021,($ millions)
      • 5.1.3.5. Global drug discovery market, 2014-2021,($ millions)
      • 5.1.3.6. Global other protein microarray market, 2014-2021,($ millions)
    • 5.1.4. Global other array market by application, 2014-2021,($ millions)
      • 5.1.4.1. Global expression profiling market, 2014-2021,($ millions)
      • 5.1.4.2. Global cancer diagnostic market , 2014-2021,($ millions)
      • 5.1.4.3. Global toxico genomics market, 2014-2021,($ millions)
      • 5.1.4.4. Global genomics market, 2014-2021,($ millions)
      • 5.1.4.5. Global drugs discovery market, 2014-2021,($ millions)
      • 5.1.4.6. Global other array market, 2014-2021,($ millions)
  • 5.2. Global biochip market by type, 2014-2021,($ millions)
    • 5.2.1. Global protein microarray market by types, 2014-2021,($ millions)
      • 5.2.1.1. Global expressional protein microarray market , 2014-2021,($ millions)
        • 5.2.1.1.1. Global functional protein microarray market, 2014-2021,($ millions)
        • 5.2.1.1.2. Global reverse phase protein microarray market, 2014-2021,($ millions)
    • 5.2.2. Global other array market by types, 2014-2021,($ millions)
      • 5.2.2.1. Global cell array market , 2014-2021,($ millions)
      • 5.2.2.2. Global tissue array market , 2014-2021,($ millions)
        • 5.2.2.2.1. Global FFPE arrays market , 2014-2021,($ millions)
        • 5.2.2.2.2. Global frozen arrays market , 2014-2021,($ millions)
  • 5.3. Global biochip market by end user, 2014-2021,($ millions)
    • 5.3.1. Research and development tools
    • 5.3.2. Drug discovery and development
    • 5.3.3. Diagnostic centers
    • 5.3.4. Sequencing and other

6. Competitive Landscape

  • 6.1. Market share
  • 6.2. Strategy - An analysis across tiers

7. Geographical analysis

  • 7.1. North America market, 2014-2021,($millions)
    • 7.1.1. United States (U.S.) market, 2014-2021,($millions)
    • 7.1.2. Canada market, 2014-2021,($millions)
  • 7.2. Europe market, 2014-2021,($millions)
    • 7.2.1. United Kingdom (UK) market, 2014-2021,($millions)
    • 7.2.2. France market, 2014-2021,($millions)
    • 7.2.3. Germany market, 2014-2021,($millions)
    • 7.2.4. Spain market, 2014-2021,($millions)
    • 7.2.5. Italy market, 2014-2021,($millions)
    • 7.2.6. RoE market, 2014-2021,($millions)
  • 7.3. Asia Pacific market, 2014-2021,($millions)
    • 7.3.1. India market, 2014-2021,($millions)
    • 7.3.2. China market, 2014-2021,($millions)
    • 7.3.3. Japan market, 2014-2021,($millions)
    • 7.3.4. Korea market, 2014-2021,($millions)
    • 7.3.5. Australia market, 2014-2021,($millions)
    • 7.3.6. RoAPAC market, 2014-2021,($millions)
  • 7.4. Rest of the world market, 2014-2021,($millions)
    • 7.4.1. Latin America market, 2014-2021,($millions)
    • 7.4.2. MENA market, 2014-2021,($millions)
    • 7.4.3. Africa market, 2014-2021,($millions)

8. Company Profiling: - (Over, SCOT analysis, strategic review)

  • 8.1. Agilent technologies
  • 8.2. Affymetrix inc
  • 8.3. Gene system inc
  • 8.4. Agendia BV inc
  • 8.5. Customarray inc
  • 8.6. Digital genomics inc
  • 8.7. Bio chain institute Inc
  • 8.8. Biomerieux SA
  • 8.9. Bio-rad laboratories inc
  • 8.10. Cepheid Inc
  • 8.11. Caliper life sciences inc
  • 8.12. Cybrdi inc
  • 8.13. EMD Millipore
  • 8.14. Elim Biopharmaceuticals
  • 8.15. Falcon Genomics.
  • 8.16. Genalyte
  • 8.17. Oxford gene technology
  • 8.18. Wafergen biosystems inc
  • 8.19. Predictive biosciences
  • 8.20. Fluidigm corp
  • 8.21. Gamida for life group
  • 8.22. Illumina Inc
  • 8.23. Life technologies corp
  • 8.24. Origene technologies Inc
  • 8.25. Perkinelmer inc
  • 8.26. Roche nimblegen inc
  • 8.27. Sequenom
  • 8.28. Sigma aldrich corp
  • 8.29. Imgenex
  • 8.30. ISU ABXIS co. ltd
  • 8.31. Quantalife inc
Back to Top